로딩 중…
지수 로딩 중…
헬릭스미스
084990· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,655-4.41%
2026-06-19
Price Chart
헬릭스미스+63.05%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 214.56B KRW |
| Revenue | 2.22B KRW |
| Net Income | 3.00B KRW |
| Total Assets | 141.94B KRW |
| Net Assets | 140.28B KRW |
| Employees | 44 |
| Value | |
| P/E | 71.61x |
| P/B | 1.53x |
| P/S | 96.54x |
| FCF Yield | -3.31% |
| Profitability | |
| ROE | 2.14% |
| ROA | 2.11% |
| Op. Margin | -415.62% |
| Revenue Growth | -40.36% |
| Financial Health | |
| Debt Ratio | 101.19% |
| Total Debt | 0 KRW |
| FCF | -7.11B KRW |
| Cash | 31.08B KRW |
| Current Ratio | 107.85x |
| Performance | |
| 1Y Return | 63.05% |
| 1M Return | -33.02% |
| From 52W High | -53.26% |
| 1Y MDD | -52.80% |
| Trading | |
| Volume | 253,769 shares |
| Foreign Own. | 2.98% |
| Per Share | |
| EPS | -7 KRW |
| BPS | 3,056 KRW |
Company Info
Established in 1996, this R&D company was listed on KOSDAQ in 2005. It possesses global biotech-level resources and capabilities spanning from candidate substance discovery to preclinical trials, analysis, and production. The company provides diverse platform-based services, leveraging its experience with US FDA Orphan Drug, Fast Track, and RMAT designations. Building on its new material development expertise, it conducts B2B businesses for health functional foods and premium cosmetics. Helixmith is headquartered in Gangseo-gu, Seoul.